I listened to couple webcasts - lots going on with the company, leading position in a huge growing segment.
I expect a buyout soon, any big pharma wants an edge in the generic and follow-on biologic must be looking hard.
Momenta has done a good job of explaining its position to the street so why haven't they bitten? There must be some reason that the larger houses aren't backing Momenta.
Market Data 
Markets 
AI
